Liquid chromatographic tandem mass spectrometric assay for simultaneous quantification of compound 97/78 and its in vivo metabolite 97/63, a novel trioxane antimalarial, in human plasma and its application to a protein binding study

Hari Narayan Kushwaha; Nagsen Gautam; Shio Kumar Singh

doi:10.1055/s-0031-1296222

Arzneimittelforschung, Table of Contents

Arzneimittelforschung 2011; 61(7): 425-432
DOI: 10.1055/s-0031-1296222

Antibiotics · Antimycotics · Antiparasitics · Antiviral Drugs · Chemotherapeutics · Cytostatics

Editio Cantor Verlag Aulendorf (Germany)

Liquid chromatographic tandem mass spectrometric assay for simultaneous quantification of compound 97/78 and its in vivo metabolite 97/63, a novel trioxane antimalarial, in human plasma and its application to a protein binding study

Hari Narayan Kushwaha

¹Pharmacokinetics and Metabolism Division, Central Drug Research Institute, CSIR, Lucknow,, India

,

Nagsen Gautam

¹Pharmacokinetics and Metabolism Division, Central Drug Research Institute, CSIR, Lucknow,, India

,

Shio Kumar Singh

¹Pharmacokinetics and Metabolism Division, Central Drug Research Institute, CSIR, Lucknow,, India

› Author Affiliations

Abstract

A sensitive, selective and specific LC-MS/ MS assay for simultaneous quantification of compound 97/78 and its active in vivo metabolite 97/63, a novel 1,2,4-trioxane antimalarial, in human plasma has been developed and validated using a-arteether as internal standard (IS). Extraction from plasma involves a simple protein precipitation method. The analytes were chromatographed on a Columbus C₁₈ column with guard by isocratic elution with acetonitrile:ammonium acetate buffer (10 mM, pH 4.0) (80:20 v/v) as mobile phase at a flow rate of 0.45 mL min⁻¹ and analyzed in multiple reactionmonitoring (MRM) positive ion mode. The chromatographic run time was 4.0 min. The weighted (1/×²) calibration curves were linear over a range of 1.56200 ng mL⁻¹ with correlation coefficients > 0.998. For both analytes, the limit of detection (LOD) and lower limit of quantification (LLOQ) were 0.5 ng mL⁻¹ and 1.56 ng mL⁻¹, respectively. The recovery of 97/78, 97/63 and IS from spiked control samples were > 90% and their matrix suppression obtained were < 8%. The accuracy (% bias) and precision (% RSD) for both analytes were < 6.78%. Both analytes were stable after three freeze-thaw cycles (% deviation < 12.80), long-term for 30 days in plasma at −60 °C (% deviation < 14.38), for 8 h on bench top in plasma at ambient temperature (% deviation < 1.52) and also in the auto-sampler for 12 h (% deviation < 3.9%). The validated method was successfully applied to a protein binding study of compound 97/78 and metabolite 97/63 in human plasma. Furthermore, the validated method will be applicable to pharmacokinetics, bioavailability and metabolism in various clinical phases and in drug interaction studies.

Key words

Antimalarial drug - Human plasma - LC-MS/MS - Metabolite - Protein binding - Stability

Full Text

References

References
1 Bunnag D, Harinasuta T. The current status of drug resistance in malaria. Int J for Parasitol 1987; 17: 169-80
2 Lell B, Luckner D, Ndjave M, Scott T, Kremsner PC. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998; 351: 709-13
3 Yikang W. How Might Qinghaosu (Artemisinin) and Related Compounds Kill the Intraerythrocytic Malaria Parasite? A Chemist’s View. Acc Chem Res 2002; 35: 255-9
4 Robert A, Odile DC, Cazelles J, Meunier B. From mechanistic studies on artemisinin derivatives to new modular antimalarial drugs. Acc Chem Res 2002; 35: 167-74
5 Cheng F, Shen J, Luo X, Zhu W, Gu J, Ji R, Jiang H, Chen K. Molecular docking and 3-d-qsar studies on the possible antimalarial mechanism of artemisinin analogues. Bioorg Med Chem 2002; 10: 2883-91
6 Singh C, Puri SK. inventors; Council of Scientific and Industrial Research, India, assignee. Substituted 1,2,4-trioxanes as antimalarial agents and a process of producing the substituted 1,2,4-trioxane. United State Patent US 6316493 (B1) 2001;
7 Olliaro R, Wells TNC. The global portfolio of new antimalarial medicines under development. Clin Pharmacol Ther 2009; 85: 584-95
8 Singh C, Gupta N, Puri SK. Photooxygenation of 3-aryl-2cyclohexenols: synthesis of a new series of antimalarial 1,2,4-trioxanes. Tetrahedron Lett 2005; 46: 205-7
9 Griesbeck AG, El-Idreesy TT, Hoinck LO, Lexa J, Brun R. Novel spiroanellated 1,2,4-trioxanes with high in vitro antimalarial activities. Bioorg Med Chem Lett 2005; 15: 595-7
10 Singh C, Srivastava NC, Puri SK. Synthesis and antimalarial activity of 6-cycloalkylvinyl substituted 1,2,4-trioxanes. Bioorg Med Chem 2004; 12: 5745-52
11 Patil KM, Bodhankar SL. Simultaneous determination of lamotrigine phenobarbitone, carbamazepine and phenytoin in human serum by high-performance liquid chromatography. J Pharm Biomed Anal 2005; 39: 181-6
12 Paglia G, D’Apolito O, Garofalo D, Scarano C, Corso G. Development and validation of a LC/MS/MS method for simultaneous quantification of oxcarbazepine and its main metabolites in human serum. J Chromatogr B 2007; 860: 153-9
13 Singh RP, Sabarinath S, Gautam N, Gupta RC, Singh SK. LC-MS/MS assay for quantification of 97/78 and its metabolite 97/63: A promising trioxane antimalarial in monkey plasma. J Chromatogr B 2009; 877: 2074-80
14 Almeida AM, Castel-Branco MM, Falcao AC. Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods. J Chromatogr B 2002; 774: 215-22
15 Issar M, Singh SK, Mishra B, Gupta RC. Pharmacokinetics, in-situ absorption and protein binding studies of a new neuroleptic agent centbutindole in rats. Eur J Pharm Sci 2003; 19: 105-13
16 Srivastava R, Gupta RC. In situ absorption and protein binding characteristics of CDRI-85/92, an antiulcer pharmacophore. Int J Pharm 2003; 257: 97-102
17 Khurana M, Paliwal JK, Kamboj VD, Gupta RC. Binding of centchroman with human serum as determined by charcoal adsorption method. IntJ Pharm 1999; 192: 109-14
18 Rajanikanth M, Gupta RC. LC florescence method for multiple synthetic compounds to rapidly create in vivo pharmacokinetic database utilizing “N-in-One” dosing. J Pharm Biomed Anal 2001; 26: 519-30
19 Singh RP, Sabarinath S, Singh SK, Gupta RC. A sensitive and selective liquid chromatographic tandem mass spectrometric assay for simultaneous quantification of novel trioxane antimalarials in different biomatrices using sample-pooling approach for high throughput pharmacokinetic studies. J Chromatogr B 2008; 864: 52-60
20 Kuo BS, Noord TV, Feng MR, Wright DS. Sample pooling to expedite bioanalysis and pharmacokinetic research. J Pharm Biomed Anal 1998; 16: 837-46
21 Xu W, Zhang Y, Yang M, Shen Z, Zhang X, Li H. LC-MS/MS method for the simultaneous determination of icariin and its major metabolites in rat plasma. J Pharm Biomed Anal 2007; 45: 667-72
22 Shah VP, Midha KK, Findlay JWA, Hill HM, Hulse JD, McGilveray IJ et al. Bioanalytical method validation-a revisit with a decade of progress. Pharm Res 2000; 17: 1551-7